-
1
-
-
0030962574
-
Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis
-
DOI 10.1053/gast.1997.v112.pm9178669
-
N Chiba CJ De Gara JM Wilkinson RH Hunt 1997 Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis Gastroenterology 112 1798 1810 1:STN:280:DyaK2szit1Sitw%3D%3D 10.1053/gast.1997.v112.pm9178669 9178669 (Pubitemid 27240763)
-
(1997)
Gastroenterology
, vol.112
, Issue.6
, pp. 1798-1810
-
-
Chiba, N.1
De Gara, C.J.2
Wilkinson, J.M.3
Hunt, R.H.4
-
2
-
-
0028842263
-
Effect of repeated boluses of intravenous omeprazole and primed infusions of ranitidine on 24-hour intragastric pH in healthy human subjects
-
1:CAS:528:DyaK2MXltlGrtL0%3D 10.1007/BF02065405 7851185
-
S Teyssen ST Chari J Scheid MV Singer 1995 Effect of repeated boluses of intravenous omeprazole and primed infusions of ranitidine on 24-hour intragastric pH in healthy human subjects Dig Dis Sci 40 247 255 1:CAS:528:DyaK2MXltlGrtL0%3D 10.1007/BF02065405 7851185
-
(1995)
Dig Dis Sci
, vol.40
, pp. 247-255
-
-
Teyssen, S.1
Chari, S.T.2
Scheid, J.3
Singer, M.V.4
-
3
-
-
0029093565
-
Turnover of the gastric H+, K(+)-adenosine triphosphatase alpha subunit and its effect on inhibition of rat gastric acid secretion
-
1:CAS:528:DyaK2MXos1aqtb8%3D 10.1016/0016-5085(95)90571-5 7557078
-
K Gedda D Scott M Besancon, et al. 1995 Turnover of the gastric H+, K(+)-adenosine triphosphatase alpha subunit and its effect on inhibition of rat gastric acid secretion Gastroenterology 109 1134 1141 1:CAS:528: DyaK2MXos1aqtb8%3D 10.1016/0016-5085(95)90571-5 7557078
-
(1995)
Gastroenterology
, vol.109
, pp. 1134-1141
-
-
Gedda, K.1
Scott, D.2
Besancon, M.3
-
4
-
-
22844451154
-
Systematic review: Proton-pump inhibitor failure in gastro-oesophageal reflux disease-where next?
-
1:CAS:528:DC%2BD2MXpt1Cjt70%3D 10.1111/j.1365-2036.2005.02531.x 16011666
-
R Fass M Shapiro R Dekel J Sewell 2005 Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease-where next? Aliment Pharmacol Ther 22 79 94 1:CAS:528:DC%2BD2MXpt1Cjt70%3D 10.1111/j.1365-2036.2005. 02531.x 16011666
-
(2005)
Aliment Pharmacol Ther
, vol.22
, pp. 79-94
-
-
Fass, R.1
Shapiro, M.2
Dekel, R.3
Sewell, J.4
-
5
-
-
21344468618
-
Primary-care physicians' perceptions and practices on the management of GERD: Results of a national survey
-
DOI 10.1111/j.1572-0241.2005.41364.x
-
WD Chey JM Inadomi AM Booher, et al. 2005 Primary-care physicians' perceptions and practices on the management of GERD: results of a national survey Am J Gastroenterol 100 1237 1242 10.1111/j.1572-0241.2005.41364.x 15929751 (Pubitemid 40904343)
-
(2005)
American Journal of Gastroenterology
, vol.100
, Issue.6
, pp. 1237-1242
-
-
Chey, W.D.1
Inadomi, J.M.2
Booher, A.M.3
Sharma, V.K.4
Fendrick, A.M.5
Howden, C.W.6
-
6
-
-
28944444479
-
Correct and incorrect dosing of proton pump inhibitors and its impact on GERD symptoms
-
10.1016/S0016-5085(03)81145-9
-
J Pezanoski N Guanaratnam M Cowen 2003 Correct and incorrect dosing of proton pump inhibitors and its impact on GERD symptoms Gastroenterology 124 Suppl 1 A228 10.1016/S0016-5085(03)81145-9
-
(2003)
Gastroenterology
, vol.124
, Issue.SUPPL. 1
, pp. 228
-
-
Pezanoski, J.1
Guanaratnam, N.2
Cowen, M.3
-
7
-
-
28944449208
-
Review article: The unmet needs in delayed-release proton-pump inhibitor therapy in 2005
-
1:CAS:528:DC%2BD28Xkt1CmsQ%3D%3D 10.1111/j.1365-2036.2005.02715.x 16303032
-
RH Hunt 2005 Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005 Aliment Pharmacol Ther 22 Suppl 3 10 19 1:CAS:528:DC%2BD28Xkt1CmsQ%3D%3D 10.1111/j.1365-2036.2005.02715.x 16303032
-
(2005)
Aliment Pharmacol Ther
, vol.22
, Issue.SUPPL. 3
, pp. 10-19
-
-
Hunt, R.H.1
-
8
-
-
77957892163
-
Non-steroidal anti-inflammatory drug related injury of the gastrointestinal tract: Clinical picture pathogenesis and prevention
-
in press
-
Scarpignato C, Hunt RH: Non-steroidal anti-inflammatory drug related injury of the gastrointestinal tract: clinical picture pathogenesis and prevention. Gastroenterol Clin North Am 2010, in press.
-
(2010)
Gastroenterol Clin North Am
-
-
Scarpignato, C.1
Hunt, R.H.2
-
9
-
-
58149310707
-
Symptoms in patients on long-term proton pump inhibitors: Prevalence and predictors
-
Patients often suffer ongoing moderate or severe symptoms when on long-term treatment. GERD and uninvestigated dyspepsia were associated with poor long-term symptom control
-
• Raghunath AS, Hungin AP, Mason J, Jackson W: Symptoms in patients on long-term proton pump inhibitors: prevalence and predictors. Aliment Pharmacol Ther 2009, 29:431-439. Patients often suffer ongoing moderate or severe symptoms when on long-term treatment. GERD and uninvestigated dyspepsia were associated with poor long-term symptom control.
-
(2009)
Aliment Pharmacol Ther
, vol.29
, pp. 431-439
-
-
Raghunath, A.S.1
Hungin, A.P.2
Mason, J.3
Jackson, W.4
-
10
-
-
55649097175
-
The proportion of patients who are free of reflux symptoms during the initial days of treatment with proton pump inhibitors (PPIs) in GERD trials: A meta-analysis
-
Abstract S1085
-
Yuan Y, Wang CC, Yuan Y, Hunt RH: The proportion of patients who are free of reflux symptoms during the initial days of treatment with proton pump inhibitors (PPIs) in GERD trials: a meta-analysis. Gastroenterology 2008; 134(4, Suppl 1):A174. Abstract S1085.
-
(2008)
Gastroenterology
, vol.134
, Issue.4 SUPPL. 1
-
-
Yuan, Y.1
Wang, C.C.2
Yuan, Y.3
Hunt, R.H.4
-
11
-
-
78649908434
-
Hunt RH: Nonhealed rate of moderate-severe (LA Classification Grade C and D) erosive esophagitis after 4-8 weeks proton pump inhibitors (PPIs): Evidence of an unmet need
-
Y Yuan B Vinh 2009 Hunt RH: Nonhealed rate of moderate-severe (LA Classification Grade C and D) erosive esophagitis after 4-8 weeks proton pump inhibitors (PPIs): evidence of an unmet need Gastroenterology 136 Suppl A440
-
(2009)
Gastroenterology
, vol.136
, Issue.SUPPL.
, pp. 440
-
-
Yuan, Y.1
Vinh, B.2
-
12
-
-
0033548841
-
Importance of pH control in the management of GERD
-
DOI 10.1001/archinte.159.7.649
-
RH Hunt 1999 Importance of pH control in the management of GERD Arch Intern Med 159 649 657 1:STN:280:DyaK1M3jtlWisw%3D%3D 10.1001/archinte.159.7.649 10218743 (Pubitemid 29177653)
-
(1999)
Archives of Internal Medicine
, vol.159
, Issue.7
, pp. 649-657
-
-
Hunt, R.H.1
-
13
-
-
68049089445
-
Hunt RH: Intragastric pH holding time pH∈<∈3 at steady state in healthy volunteers (HV) after once daily PPIs: A predictor for low erosive esophagitis (EE) healing rates?
-
Y Yuan 2009 Hunt RH: Intragastric pH holding time pH∈<∈3 at steady state in healthy volunteers (HV) after once daily PPIs: a predictor for low erosive esophagitis (EE) healing rates? Gastroenterology 136 Suppl M1990
-
(2009)
Gastroenterology
, vol.136
, Issue.SUPPL.
, pp. 1990
-
-
Yuan, Y.1
-
14
-
-
68049103749
-
Night-time pH holding time: What is hidden by the% of time pH∈≥∈4?
-
CC Wang Y Yuan Y Chen RH Hunt 2008 Night-time pH holding time: what is hidden by the% of time pH∈≥∈4? Am J Gastroenterol 103 Suppl 1 S51
-
(2008)
Am J Gastroenterol
, vol.103
, Issue.SUPPL. 1
, pp. 51
-
-
Wang, C.C.1
Yuan, Y.2
Chen, Y.3
Hunt, R.H.4
-
15
-
-
50249186798
-
Yield of 24-hour esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy
-
10.1007/s10620-007-0186-6 18322797
-
G Karamanolis T Vanuytsel D Sifrim, et al. 2008 Yield of 24-hour esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy Dig Dis Sci 53 2387 2393 10.1007/s10620-007-0186-6 18322797
-
(2008)
Dig Dis Sci
, vol.53
, pp. 2387-2393
-
-
Karamanolis, G.1
Vanuytsel, T.2
Sifrim, D.3
-
16
-
-
55649107574
-
Hunt RH: Intragastric acid suppressing effect of proton pump inhibitors twice daily at steady state in healthy volunteers: Evidence of an unmet need?
-
Y Yuan 2008 Hunt RH: Intragastric acid suppressing effect of proton pump inhibitors twice daily at steady state in healthy volunteers: evidence of an unmet need? Am J Gastroenterol 103 Suppl S50
-
(2008)
Am J Gastroenterol
, vol.103
, Issue.SUPPL.
, pp. 50
-
-
Yuan, Y.1
-
17
-
-
33744985235
-
Reflux events and sleep: Are we vulnerable?
-
10.1007/s11894-006-0076-7 16764786
-
WC Orr 2006 Reflux events and sleep: are we vulnerable? Curr Gastroenterol Rep 8 202 207 10.1007/s11894-006-0076-7 16764786
-
(2006)
Curr Gastroenterol Rep
, vol.8
, pp. 202-207
-
-
Orr, W.C.1
-
18
-
-
33750466191
-
The patient with refractory gastroesophageal reflux disease
-
DOI 10.1111/j.1442-2050.2006.00619.x
-
JE Richter 2006 The patient with refractory gastroesophageal reflux disease Dis Esophagus 19 443 447 1:STN:280:DC%2BD28njsVWruw%3D%3D 10.1111/j.1442-2050.2006.00619.x 17069586 (Pubitemid 44644679)
-
(2006)
Diseases of the Esophagus
, vol.19
, Issue.6
, pp. 443-447
-
-
Richter, J.E.1
-
20
-
-
4344654345
-
Intragastric acid suppression and pharmacokinelics of twice-daily esomeprazole: A randomized, three-way crossover study
-
DOI 10.1111/j.1365-2036.2004.02079.x
-
PO Katz DO Castell Y Chen, et al. 2004 Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study Aliment Pharmacol Ther 20 399 406 1:CAS:528:DC%2BD2cXnvVyjtrs%3D 10.1111/j.1365-2036.2004.02079.x 15298633 (Pubitemid 39120250)
-
(2004)
Alimentary Pharmacology and Therapeutics
, vol.20
, Issue.4
, pp. 399-406
-
-
Katz, P.O.1
Castell, D.O.2
Chen, Y.3
Andersson, T.4
Sostek, M.B.5
-
21
-
-
56349135772
-
Nighttime symptoms and sleep impairment among patients with gastro-esophageal reflux disease (GERD) receiving prescription (Rx) proton pump inhibitors (PPIs)
-
WD Chey R Mody L Chen, et al. 2008 Nighttime symptoms and sleep impairment among patients with gastro-esophageal reflux disease (GERD) receiving prescription (Rx) proton pump inhibitors (PPIs) Gastroenterology 134 4 Suppl 1 A323 A324
-
(2008)
Gastroenterology
, vol.134
, Issue.4 SUPPL. 1
-
-
Chey, W.D.1
Mody, R.2
Chen, L.3
-
22
-
-
0038796092
-
Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: The results of a Gallup survey conducted on behalf of the American Gastroenterological Association
-
10.1111/j.1572-0241.2003.07531.x
-
R Shaker DO Castell PS Schoenfeld SJ Spechler 2003 Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association Am J Gastroenterol: 98 1487 1493 10.1111/j.1572-0241.2003.07531.x
-
(2003)
Am J Gastroenterol
, vol.98
, pp. 1487-1493
-
-
Shaker, R.1
Castell, D.O.2
Schoenfeld, P.S.3
Spechler, S.J.4
-
23
-
-
68049104246
-
Evolving issues in the management of reflux disease?
-
Although GERD is common, management still poses many challenges, which are addressed in this paper together with the unmet needs in reflux disease
-
• Yuan Y, Hunt RH Evolving issues in the management of reflux disease? Curr Opin Gastroenterol 2009, 25:342-351. Although GERD is common, management still poses many challenges, which are addressed in this paper together with the unmet needs in reflux disease.
-
(2009)
Curr Opin Gastroenterol
, vol.25
, pp. 342-351
-
-
Yuan, Y.1
Hunt, R.H.2
-
24
-
-
3042544378
-
+)-ATPase by proton pump inhibitors
-
DOI 10.1021/ja049607w
-
JM Shin YM Cho G Sachs 2004 Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors J Am Chem Soc 126 7800 7811 1:CAS:528:DC%2BD2cXksFelt7g%3D 10.1021/ja049607w 15212527 (Pubitemid 38812770)
-
(2004)
Journal of the American Chemical Society
, vol.126
, Issue.25
, pp. 7800-7811
-
-
Shin, J.M.1
Cho, Y.M.2
Sachs, G.3
-
25
-
-
32144435586
-
+-ATPase in vitro and in vivo
-
DOI 10.1016/j.bcp.2005.11.030, PII S0006295205007938
-
JM Shin M Homerin F Domagala H Ficheux G Sachs 2006 Characterization of the inhibitory activity of tenatoprazole on the gastric H+, K∈+∈- ATPase in vitro and in vivo Biochem Pharmacol 71 837 849 1:CAS:528: DC%2BD28XhtlKmtLg%3D 10.1016/j.bcp.2005.11.030 16405921 (Pubitemid 43208840)
-
(2006)
Biochemical Pharmacology
, vol.71
, Issue.6
, pp. 837-849
-
-
Shin, J.M.1
Homerin, M.2
Domagala, F.3
Ficheux, H.4
Sachs, G.5
-
26
-
-
7444242617
-
+-ATPase in vivo
-
DOI 10.1016/j.bcp.2004.07.035, PII S0006295204005581
-
JM Shin G Sachs 2004 Differences in binding properties of two proton pump inhibitors on the gastric H+, K∈+∈-ATPase in vivo Biochem Pharmacol 68 2117 2127 1:CAS:528:DC%2BD2cXovV2hurk%3D 10.1016/j.bcp.2004.07.035 15498502 (Pubitemid 39446139)
-
(2004)
Biochemical Pharmacology
, vol.68
, Issue.11
, pp. 2117-2127
-
-
Shin, J.M.1
Sachs, G.2
-
27
-
-
1842429772
-
Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: Effects on intragastric pH and comparison with esomeprazole in healthy volunteers
-
DOI 10.1111/j.1365-2036.2004.01893.x
-
JP Galmiche 2004 Bruley Des Varannes S, Ducrotté P, et al.: Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers Aliment Pharmacol Ther 19 655 662 1:CAS:528:DC%2BD2cXjslyhurg%3D 10.1111/j.1365-2036.2004.01893.x 15023167 (Pubitemid 38445426)
-
(2004)
Alimentary Pharmacology and Therapeutics
, vol.19
, Issue.6
, pp. 655-662
-
-
Galmiche, J.P.1
Bruley Des Varannes, S.2
Ducrotte, P.3
Sacher-Huvelin, S.4
Vavasseur, F.5
Taccoen, A.6
Fiorentini, P.7
Homerin, M.8
-
28
-
-
15044357829
-
A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers
-
DOI 10.1111/j.1365-2036.2005.02381.x
-
JP Galmiche S Sacher-Huvelin 2005 Bruley des Varannes S, et al.: A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers Aliment Pharmacol Ther 21 575 582 1:CAS:528:DC%2BD2MXjt12ksrs%3D 10.1111/j.1365-2036.2005.02381.x 15740541 (Pubitemid 40381509)
-
(2005)
Alimentary Pharmacology and Therapeutics
, vol.21
, Issue.5
, pp. 575-582
-
-
Galmiche, J.P.1
Sacher-Huvelin, S.2
Bruley Des Varannes, S.3
Vavasseur, F.4
Taccoen, A.5
Fiorentini, P.6
Homerin, M.7
-
29
-
-
63849135186
-
Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: A combined analysis of randomized controlled clinical trials
-
1:CAS:528:DC%2BD1MXltVWmsbc%3D 10.1185/03007990802693883 19232037
-
M Vakily W Zhang J Wu, et al. 2009 Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials Curr Med Res Opin 25 627 638 1:CAS:528:DC%2BD1MXltVWmsbc%3D 10.1185/03007990802693883 19232037
-
(2009)
Curr Med Res Opin
, vol.25
, pp. 627-638
-
-
Vakily, M.1
Zhang, W.2
Wu, J.3
-
30
-
-
61849139946
-
Clinical trials: Healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation-results from two randomized controlled studies
-
This study showed that dexlansoprazole MR is highly effective in healing erosive esophagitis and offers benefits over lansoprazole, particularly in moderate-to-severe disease
-
• Sharma P, Shaheen NJ, Perez MC, et al.: Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation-results from two randomized controlled studies. Aliment Pharmacol Ther 2009, 29:731-741. This study showed that dexlansoprazole MR is highly effective in healing erosive esophagitis and offers benefits over lansoprazole, particularly in moderate-to-severe disease.
-
(2009)
Aliment Pharmacol Ther
, vol.29
, pp. 731-741
-
-
Sharma, P.1
Shaheen, N.J.2
Perez, M.C.3
-
31
-
-
70349687374
-
Clinical trial: Efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis-maintenance of healing and symptom relief
-
1:CAS:528:DC%2BD1MXhtl2kurrE 10.1111/j.1365-2036.2009.04119.x 19681809
-
CW Howden LM Larsen MC Perez, et al. 2009 Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis- maintenance of healing and symptom relief Aliment Pharmacol Ther 30 895 907 1:CAS:528:DC%2BD1MXhtl2kurrE 10.1111/j.1365-2036.2009.04119.x 19681809
-
(2009)
Aliment Pharmacol Ther
, vol.30
, pp. 895-907
-
-
Howden, C.W.1
Larsen, L.M.2
Perez, M.C.3
-
32
-
-
45549091042
-
Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z
-
This study showed that a PPI prodrug, AGN201904-Z, provided superior acid control over esoemprazole. Longer duration of the effective plasma concentration of drug was achieved by slow absorption of the prodrug
-
• Hunt RH, Armstrong D, Yaghoobi M, et al.: Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment Pharmacol Ther 2008, 28:187-199. This study showed that a PPI prodrug, AGN201904-Z, provided superior acid control over esoemprazole. Longer duration of the effective plasma concentration of drug was achieved by slow absorption of the prodrug.
-
(2008)
Aliment Pharmacol Ther
, vol.28
, pp. 187-199
-
-
Hunt, R.H.1
Armstrong, D.2
Yaghoobi, M.3
-
33
-
-
28144455089
-
Tolerability, pharmacokinetics and effects on gastric acid secretion after single oral doses of the potassium-competitive acid blocker AZD0865 in healthy male subjects
-
C Nilsson E Albrektson H Rydholm, et al. 2005 Tolerability, pharmacokinetics and effects on gastric acid secretion after single oral doses of the potassium-competitive acid blocker AZD0865 in healthy male subjects Gastroenterology 128 4 Suppl 2 A528
-
(2005)
Gastroenterology
, vol.128
, Issue.4 SUPPL. 2
, pp. 528
-
-
Nilsson, C.1
Albrektson, E.2
Rydholm, H.3
-
34
-
-
37849036310
-
A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease
-
This article provides a comparison of a short acting K-competitive inhibitor of the H,K-ATPase with a PPI
-
• Dent J, Kahrilas PJ, Hatlebakk J, et al.: A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol 2008, 103:20-26. This article provides a comparison of a short acting K-competitive inhibitor of the H,K-ATPase with a PPI.
-
(2008)
Am J Gastroenterol
, vol.103
, pp. 20-26
-
-
Dent, J.1
Kahrilas, P.J.2
Hatlebakk, J.3
-
35
-
-
36549032595
-
A Randomized, Comparative Study of Three Doses of AZD0865 and Esomeprazole for Healing of Reflux Esophagitis
-
DOI 10.1016/j.cgh.2007.08.014, PII S1542356507007720
-
PJ Kahrilas J Dent K Lauritsen, et al. 2007 A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis Clin Gastroenterol Hepatol 5 1385 1391 1:CAS:528: DC%2BD1cXlslSrtQ%3D%3D 10.1016/j.cgh.2007.08.014 17950677 (Pubitemid 350181597)
-
(2007)
Clinical Gastroenterology and Hepatology
, vol.5
, Issue.12
, pp. 1385-1391
-
-
Kahrilas, P.J.1
Dent, J.2
Lauritsen, K.3
Malfertheiner, P.4
Denison, H.5
Franzen, S.6
Hasselgren, G.7
-
36
-
-
34248593276
-
Soraprazan: Setting new standards in inhibition of gastric acid secretion
-
DOI 10.1124/jpet.107.120428
-
WA Simon M Herrmann T Klein, et al. 2007 Soraprazan: setting new standards in inhibition of gastric acid secretion J Pharmacol Exp Ther 321 866 874 1:CAS:528:DC%2BD2sXmsFGntLw%3D 10.1124/jpet.107.120428 17369284 (Pubitemid 46762698)
-
(2007)
Journal of Pharmacology and Experimental Therapeutics
, vol.321
, Issue.3
, pp. 866-874
-
-
Simon, W.A.1
Herrmann, M.2
Klein, T.3
Shin, J.M.4
Huber, R.5
Senn-Bilfinger, J.6
Postius, S.7
-
37
-
-
70549087723
-
-
inventors; Takeda Pharmaceutical Company, assignee Japanese patent WO 2008/108380 A2. September 12
-
Kajino M, Nishida H, Arikawa Y, Hirase K, Ono K, inventors; Takeda Pharmaceutical Company, assignee. Pyrrole compounds. Japanese patent WO 2008/108380 A2. September 12, 2008.
-
(2008)
Pyrrole Compounds
-
-
Kajino, M.1
Nishida, H.2
Arikawa, Y.3
Hirase, K.4
Ono, K.5
-
38
-
-
77957228369
-
1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1 H-pyrrol-3-yl]-N- methylmet hanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases
-
Epub ahead of print
-
Hori Y, Imanishi A, Matsukawa J, et al.: 1-[5-(2-Fluorophenyl)-1- (pyridin-3-ylsulfonyl)-1 H-pyrrol-3-yl]-N-methylmet hanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther 2010 (Epub ahead of print).
-
(2010)
J Pharmacol Exp Ther
-
-
Hori, Y.1
Imanishi, A.2
Matsukawa, J.3
|